GAITHERSBURG, MD.

If granted, Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) would be the first protein-based option for adolescents aged 12-17 years in Europe Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced submission of its request to expand the conditional marketing authorization (CMA) of Nuvaxovid™ COVID-19 Vaccine (recombinant,…

–  ‘We Do Vaccines’ and ‘Know Our Vax’ are new educational efforts that provide information regarding vaccines –  Programs explain Novavax’ commitment to vaccine development and innovation Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the launch of its global unbranded ‘We…

– NVX-CoV2373 demonstrates protection against symptomatic and asymptomatic infection – High level of vaccine efficacy maintained over a 6-month period of surveillance  – Continued reassuring safety profile in line with previous trials Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today shared extended analysis from its…

– PREVENT-19 pediatric expansion in adolescents aged 12 through 17 achieved primary effectiveness endpoint demonstrating comparability to adult population – Trial demonstrated 82% clinical efficacy against Delta variant – Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied – Vaccine was well-tolerated with no safety signals identified – Novavax plans to…

Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted)▼ is the first protein-based COVID-19 vaccine authorized in Great Britain Novavax and the U.K. Vaccines Taskforce previously announced an agreement for up to 60 million doses Authorization based on data including an ongoing pivotal Phase 3 trial conducted in the U.K. with almost 15,000 participants Novavax, Inc. (Nasdaq: NVAX), a […]

– Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants – Third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials, with a 9.3-fold IgG rise and a 19.9-fold ACE2 inhibition increase after booster dose – Immune responses in adolescents were 2- to […]

– WHO Strategic Advisory Group of Experts on Immunization (SAGE) recommends primary two-dose vaccination series of NVX-CoV2373 in persons aged 18 and older – SAGE recommends additional third dose of NVX-CoV2373 administered to immunocompromised persons – Recommendation follows grant of WHO Emergency Use Listing for Novavax’ vaccine Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and…

– Nuvaxovid™ COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]) listed for emergency use by the WHO – EUL for Nuvaxovid complements listing for Novavax vaccine manufactured and marketed by Serum Institute of India as Covovax™ – EUL by WHO is a prerequisite for exports to numerous countries participating in the COVAX Facility Novavax, Inc. (Nasdaq: NVAX), a biotechnology company […]

Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) is the first protein-based COVID-19 vaccine authorized for use in Europe Novavax and the European Commission previously announced an advance purchase agreement for up to 200 million doses through 2023 Authorization follows positive recommendation by European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) Novavax, Inc. (Nasdaq: NVAX), […]